Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review.

Basic Clin Pharmacol ToxicolOct 3, 2026
Clinical ResearchNephrologyEndocrinology

Huriye Seyma Kafa, Sabina Chaudhary Hauge, Ditte Hansen

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the efficacy and safety of anabolic parathyroid hormone (PTH) treatments in patients with chronic kidney disease (CKD) Stages 4-5D. Two randomized controlled trials were included, indicating that teriparatide improved bone mineral density (BMD) at the lumbar spine and femoral neck in CKD Stage 4, and at the total hip in CKD Stage 5D. However, adverse events were more frequent in the teriparatide group.

Key findings

  • Teriparatide improved BMD at the lumbar spine and femoral neck in CKD Stage 4 patients.
  • In CKD Stage 5D, teriparatide significantly improved BMD at the total hip compared to controls.
  • Adverse events were observed more frequently in the teriparatide-treated group.

Why it matters

Patients with chronic kidney disease are at increased risk for fractures due to osteoporosis. Understanding the potential benefits and risks of anabolic treatments like teriparatide is crucial for managing bone health in this population.

Source

PubMed · PMID 42825520

Published in Basic Clin Pharmacol Toxicol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.